Engineered immune cells take on Hard-to-Treat cancers
NCT ID NCT06658951
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study is testing a new treatment called Anti-HER2 CAR-T cells in 30 adults with advanced solid tumors that have the HER2 protein and have not responded to standard treatments. Participants first receive chemotherapy, then an infusion of the engineered immune cells. The main goals are to check safety and find the right dose, while also seeing if tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-HER2 CAR-T cells (a type of immune cell therapy) given after chemotherapy
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced HER2-positive cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early, small exploratory study (30 participants) focused on safety, not effectiveness. CAR-T therapy can cause severe side effects like cytokine release syndrome, and it may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE ADVANCED MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China